Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

55 results about "Colistin" patented technology

Colistin, also known as polymyxin E, is an antibiotic produced by certain strains of the bacteria Paenibacillus polymyxa. Colistin is a mixture of the cyclic polypeptides colistin A and B and belongs to the class of polypeptide antibiotics known as polymyxins. Colistin is effective against most Gram-negative bacilli.

Multiplex PCR (Polymerase Chain Reaction) detection kit and method for rapidly detecting common antibiotic-resistant bacteria

The invention discloses a multiplex PCR (Polymerase Chain Reaction) detection kit and a multiplex PCR detection method for rapidly detecting common antibiotic-resistant bacteria. The kit comprises a primer pair blaCTX-M-F and a primer pair blaCTX-M-R, wherein the primer pair is used for specifically amplifying a beta-lactam drug-resistant gene blaCTX-M of avian pathogenic escherichia coli; the primer pairs oqxA-F and oqxA-R are used for specifically amplifying the fluoroquinolone drug-resistant gene oqxA of the avian pathogenic escherichia coli; the primer pair aphh (3 '')-F and aphh (3'')-R is used for specifically amplifying the avian pathogenic escherichia coli aminoglycoside drug-resistant gene aphh (3 ''); the primer pairs tet (A)-F and tet (A)-R are used for specifically amplifying the tetracycline drug-resistant gene tet (A) of the avian pathogenic escherichia coli; the invention relates to a primer pair mcr-1-F and mcr-1-R for specifically amplifying a colistin drug-resistant gene mcr-1 of avian pathogenic escherichia coli. The multiplex primer provided by the invention has the advantages of difficulty in forming a dimer and a hairpin structure, uniform Tm value, moderate primer length and GC content and the like, and is beneficial to obtaining a high-quality amplification product, so that a detection result is accurate and reliable.
Owner:LONGYAN UNIV +1

Application of dronedarone hydrochloride as polymyxin synergist

The invention relates to application of dronedarone hydrochloride in preparation of a polymyxin synergist. A checkerboard method-minimum inhibitory concentration test, a growth curve test and a sterilization curve test prove that dronedarone hydrochloride and colistin have a good in-vitro synergistic antibacterial effect; an isothermal titration calorimetry test confirms that dronedarone hydrochloride can play a synergistic antibacterial role by combining cardiolipin and phosphatidyl glycerol. Meanwhile, a mouse ExPEC drug-resistant strain abdominal cavity infection model shows that the dronedarone hydrochloride can remarkably enhance the in-vivo treatment effect of the colistin. Compared with drug research and development of unknown active compounds, the dronedarone hydrochloride as a marketed drug can effectively accelerate the research and development process of new drugs and reduce the risk of drug research and development failure, which is of great significance in prolonging the antibacterial activity of existing antibiotics and solving the problem of bacterial drug resistance.
Owner:JILIN UNIVERSITY

Multi-epitope antigenic polypeptides derived from acinetobacter baumannii and immunotherapeutic uses thereof

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Application of the antithrombotic small molecule compound BPTU as a colistin adjuvant for synergistic anti-Gram-negative bacteria

The present application relates to the field of biomedicine technology, and in particular to the use of an antithrombotic small molecule compound BPTU (CAS No. 870544-59-5) as a colistin adjuvant for synergistic anti-Gram-negative bacteria, wherein the antithrombotic small molecule compound BPTU comprises a compound as shown in Formula I; the use of the antithrombotic small molecule compound BPTU as a colistin adjuvant for synergistic anti-Gram-negative bacteria, BPTU and colistin have a synergistic antibacterial effect on Gram-negative bacteria, the outer membrane of Gram-negative bacteria can act as a drug barrier, and colistin has membrane-breaking activity, and colistin breaks the barrier effect of the cell membrane to assist BPTU in entering the cell to exert its antibacterial activity. Therefore, the combined use of the antithrombotic small molecule compound BPTU and colistin has broad application prospects in the treatment of Gram-negative bacteria.
Owner:SHENZHEN UNIV

Antibacterial effect of halogenated fluorescein against colistin-resistant Gram-negative bacteria

The present invention relates to a method for treating Gram-negative bacteria that are resistant to colistin (MIC > 50 mg / mL), an antibacterial compound, excluding those of the genera Burkholderia, Proteus, and Serratia, comprising contacting the bacteria with an aqueous pharmaceutical composition containing a rose bengal (RB) compound of formula I, dissolved or dispersed at a concentration of about 0.01 to about 15 mg / mL, and irradiating the contacted bacteria with light of a wavelength of about 500 nm to about 600 nm for a period of about 1 to about 10 minutes, at a concentration of about 16 to about 160 J / cm². 2 The aim is to create a method that involves obtaining a certain amount of light to treat and kill irradiated bacteria. [Formula 1] JPEG2026511692000028.jpg5864 (where X, R 1 , R 2 (and M+ are defined herein)
Owner:PROVECTUS PHARMATECH INC +1

Metabolically engineered paenibacillus for improved production of colistin

Colistin is an important last-resort antibiotic, but its production involves significant challenges due to the presence of impurities resulting from various analogs and the limited number of native producers. In response, disclosed are mutant Paenibacillus bacteria that produce Colicin A more efficiently and / or Colicin A that is of higher purity and / or has a cleaner metabolite background. The disclosed mutant bacteria are genetically engineered to inactivate expression of one or more biosynthetic gene clusters (BGCs), increase expression of one or more other BCGs, and / or increase expression of one or more L-DABA pathway genes.
Owner:VERSITECH LTD

Application of usnic acid in preparation of anti-vibrio parahaemolyticus medicine, pharmaceutical composition and application of pharmaceutical composition

The invention provides application of usnic acid in preparation of anti-vibrio parahaemolyticus drugs, a pharmaceutical composition and application of the pharmaceutical composition, and belongs to the technical field of biological medicines. The pharmaceutical composition containing usnic acid and colistin is simple in function addition, can achieve a synergistic antibacterial effect, has an obvious synergistic antibacterial effect, and can synergistically resist vibrio parahaemolyticus. A chessboard method minimum inhibitory concentration test and a minimum bactericidal concentration test prove that the combination of usnic acid and colistin has an obvious synergistic antibacterial activity effect, and the problems of drug resistance of multi-drug-resistant gram-negative bacteria and lack of effective drugs are solved. The invention relates to new application of usnic acid and usnic acid combined with colistin in treatment of vibrio parahaemolyticus infection, and the usnic acid and the colistin have important clinical application value.
Owner:CHINA AGRI UNIV SANYA RES INST +1

Application of α-terpineol as a synergist in combating drug-resistant Enterobacteriaceae

ActiveCN118512423Bless researchSafe and effective assistanceAntibacterial agentsHydroxy compound active ingredientsDiseaseEnterobacteriaceae Infections
The present invention provides the use of α-pineneol as a synergist in combating drug-resistant Enterobacteriaceae, and belongs to the field of medical technology. Specifically, α-pineneol is used as a synergist in combination with colistin or β-lactam antibiotic meropenem to combat drug-resistant Enterobacteriaceae; the drug-resistant Enterobacteriaceae include drug-resistant Salmonella, drug-resistant Escherichia coli, and drug-resistant Klebsiella pneumoniae. The present invention provides a new use of the natural compound α-pineneol: α-pineneol can effectively enhance the sensitivity of drug-resistant Enterobacteriaceae to carbapenem antibiotics meropenem and colistin, and effectively improve the efficacy of the above-mentioned antibiotics on drug-resistant Enterobacteriaceae, which is of great significance for solving clinical drug-resistant Salmonella, drug-resistant Escherichia coli and drug-resistant Klebsiella pneumoniae infections. Provide safe and effective auxiliary drugs for the treatment of drug-resistant Enterobacteriaceae infection diseases and provide technical support for the control of bacterial resistance.
Owner:QINGDAO AGRI UNIV

Use of bms-833923 and derivatives thereof and medicaments

The application discloses application of BMS-833923 and derivatives thereof and a medicine, and belongs to the technical field of antibiotics. The BMS-833923 and the derivatives thereof can be used as colistin adjuvants to jointly inhibit or eliminate gram-negative bacteria, and can also independently inhibit or eliminate gram-positive bacteria. The gram-negative bacteria can include at least one of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, pan-drug-resistant strains BAA-1800, BAA-1794 and BAA-1792, and the gram-positive bacteria can include at least one of Staphylococcus aureus and Bacillus subtilis. By taking the BMS-833923 and the derivatives thereof as adjuvants of colistin, the therapeutic index of the colistin can be effectively expanded, and lower, non-toxic doses of the colistin can be used in clinical treatment of effective treatment of drug-resistant bacterial infections.
Owner:UNIV OF MACAU

Metabolically engineered paeniba CILL us for improved production of colistin

Colistin is an important last-resort antibiotic, but its production involves significant challenges due to the presence of impurities resulting from various analogs and the limited number of native producers. In response, disclosed are mutant Paenibacillus bacteria that produce Colicin A more efficiently and / or Colicin A that is of higher purity and / or has a cleaner metabolite background. The disclosed mutant bacteria are genetically engineered to inactivate expression of one or more biosynthetic gene clusters (BGCs), increase expression of one or more other BCGs, and / or increase expression of one or more L-DABA pathway genes.
Owner:VERSITECH LTD

Application of liquiritigenin in preparation of bactericide or antibiotic synergist

The invention discloses an application of liquiritigenin in preparation of a bactericide or an antibiotic synergist. The invention discloses the synergistic effect, the antibacterial property and the synergistic mechanism of liquiritigenin on colistin and the potential value of in-vivo combined application of liquiritigenin. On the basis, a feasible treatment scheme is provided to cope with the increasingly aggravated drug resistance problem, the use curative effect of the colistin is effectively enhanced, and the clinical service life of the colistin is prolonged. The possibility that liquiritigenin is used as a colistin synergist to resist infection of multi-drug-resistant pathogenic bacteria is reduced. The liquiritigenin can reduce the minimum inhibitory concentration of the colistin to drug-resistant gram-negative bacteria by 16 times, and the antibacterial activity of the colistin is greatly improved.
Owner:YANGZHOU UNIV

Polymyxin b and colistin highly specific haptens, artificial antigens, and methods of making and using the same

PendingCN122301997ACarrier proteinPolymyxin B
This invention relates to the field of biochemical technology, and particularly to highly specific haptens of polymyxin B and colistin, artificial antigens, their preparation methods, and applications. The haptens have structures as shown in Formula I or Formula II. The applications include: (1) preparing specific antibodies against polymyxin B or colistin; (2) detecting specific antibodies against polymyxin B or colistin; and (3) preparing reagents for detecting specific antibodies against polymyxin B or colistin. This invention further provides artificial antigens obtained by conjugating the haptens with carrier proteins. Using the artificial antigens provided by this invention as immunogens to immunize experimental animals, highly specific and sensitive antiserum can be prepared, which can then be used to extract and prepare polyclonal antibodies. These methods can be used to establish highly specific, highly sensitive, simple, and rapid detection methods for polymyxin B and colistin, and have significant application value.
Owner:CHINA AGRI UNIV

Application of Colistin in preparation of medicine for treating and preventing acute respiratory distress syndrome

PendingCN120550078ACyclic peptide ingredientsRespiratory disorderLUNG HEMORRHAGEPIEZO1
The invention relates to application of Colistin in preparation of a medicine for treating and preventing acute respiratory distress syndrome, and relates to the technical field of medicines. The Colistin effectively inhibits calcium ion cell influx by inhibiting a mechanical sensitive channel of Piezo1 protein, further prevents and reduces pathological changes such as pulmonary hemorrhage, neutrophil infiltration, pulmonary capillary hyperemia and interval thickening in the ARDS disease, plays an important role in preventing or treating the acute respiratory distress syndrome, and has a huge application prospect.
Owner:GUIZHOU MEDICAL UNIV

Analysis method for detecting colistin in bacteria

The invention belongs to the technical field of bacteria detection, and discloses an analysis method for detecting colistin in bacteria. The method comprises the following steps: firstly, centrifugally washing bacterial suspension incubated by sub-bacteriostasis colistin, and repeatedly freezing and thawing by adopting liquid nitrogen, so that bacterial cells are cracked; placing the split thalli in an acidic solution, and hydrolyzing at 60-120 DEG C in a protective atmosphere to obtain 2, 4-diaminobutyric acid; adjusting the pH to be neutral by using an alkaline solution to obtain hydrolysate; adding a derivatization buffer solution and a derivatization agent chloroformic acid-9-fluorenyl methyl ester into the hydrolysate, reacting at 20-80 DEG C to obtain a derivatization reaction solution, and treating to obtain filtrate; and separating the filtrate through a C8 reversed-phase chromatographic column, determining by selecting a fluorescence detector, and qualitatively and quantitatively analyzing the colistin in the bacteria by adopting a standard addition method, so that the colistin in the bacteria can be detected. According to the method, the colistin in the bacteria is detected by using a high performance liquid chromatography-fluorescence method, and a technical support is provided for exploring an antibacterial action mechanism of the colistin and a drug resistance mechanism of the bacteria.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

Antimicrobial association in the treatment of p. aeruginosa biofilm-associated infections

PendingUS20250325625A1Antibacterial agentsOrganic active ingredientsAeruginosa pseudomonasDisease
The present invention relates to the synergic association of colistin and N-acetylcysteine (NAC) for the treatment and eradication of mature biofilm-associated infections by P. aeruginosa. In particular the synergic association of colistin and NAC is useful for the treatment and eradication of P. aeruginosa infections in patients suffering from chronic lung diseases and recurrent P. aeruginosa infections.
Owner:ZAMBON SPA

Honeycomb-shaped PLGA (poly (lactic-co-glycolic acid)) microsphere with chitosan ambroxol coating and preparation method of honeycomb-shaped PLGA microsphere

The invention provides a honeycomb PLGA (poly (lactic-co-glycolic acid)) microsphere with a chitosan ambroxol coating and a preparation method of the honeycomb PLGA microsphere with the chitosan ambroxol coating. The honeycomb PLGA microsphere with the chitosan ambroxol coating can be loaded with drugs such as andrographolide, colistin, amphotericin B and the like. Meanwhile, by modifying the ambroxol chitosan coating on the surface of the PLGA microsphere, the respiratory tract mucus penetrating ability of the PLGA microsphere is greatly enhanced, the sequential release of the loaded medicine can be realized, the ambroxol released in the first stage can break through the respiratory tract mucus barrier of the lung, and the release effect of the ambroxol chitosan coating on the surface of the PLGA microsphere is improved. The medicine released in the second stage can play anti-inflammatory and antifungal roles and is used for preventing and treating lung infectious diseases.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1

Fermentation method for reducing non-methane hydrocarbon in colistin E fermentation tail gas

The invention discloses a fermentation method for reducing non-methane hydrocarbon in colistin E fermentation tail gas, and belongs to the technical field of biochemical engineering. The method specifically comprises the following steps: A, inoculating cultured seed liquid into a fermentation culture medium for fermentation; b, supplementing bibenzylpyridine in the fermentation process; c, stopping fermentation after fermenting for a period of time; in the step A, the inoculation amount is 1-20%, and a fermentation medium comprises the following components in parts by mass / volume (W / V): 1-10 parts of corn starch, 0.01-1 part of glucose, 1-10 parts of bean flour, 0.01-2 parts of monopotassium phosphate, 0.01-10 parts of ammonium sulfate, 0-1 part of sodium chloride, 0-1 part of magnesium sulfate, 0.01-5 parts of calcium carbonate and 0.001-1 part of liquid defoaming agent. The key technology of the invention is as follows: cultured seed liquid is inoculated into a fermentation medium for fermentation, bibenzylpyridine is supplemented in the fermentation process, and fermentation is stopped after fermentation is performed for a period of time. Wherein a small amount of bibenzylpyridine is supplemented, so that the level of non-methane total hydrocarbon can be effectively reduced, and meanwhile, the yield is favorably increased.
Owner:HEBEI SHENGXUE DACHENG TANGSHAN PHARM CO LTD

Antibiotic combination therapy

The present invention provides antibiotic combination therapies for treating Acinetobacter baumannii infection in a subject. These combination therapies comprise rifudine and a second antibiotic such as colistin and cefdinir.
Owner:BIOVERSYS AG

Application of antithrombotic small molecule compound BPTU as colistin adjuvant to synergistically resist gram-negative bacteria

The invention relates to the technical field of biological medicine, in particular to application of an antithrombotic small molecule compound BPTU (CAS number 870544-59-5) as a colistin adjuvant to synergistically resist gram-negative bacteria, and the antithrombotic small molecule compound BPTU comprises a compound as shown in a formula I; according to the application of the antithrombotic small molecule compound BPTU serving as the colistin adjuvant to synergistically resist gram-negative bacteria, the BPTU and the colistin have a synergistic antibacterial effect on the gram-negative bacteria, an extracellular membrane of the gram-negative bacteria can play a role in a drug barrier, the colistin has membrane breaking activity, the barrier effect of the cell membrane is broken by the colistin, and the effect of the drug barrier is improved. The antithrombotic micromolecular compound BPTU and colistin are combined to assist the BPTU to enter cells to exert antibacterial activity, so that the antithrombotic micromolecular compound BPTU and colistin are combined for medication and have a wide application prospect in treatment of gram-negative bacteria.
Owner:SHENZHEN UNIV

Panel for detecting antibiotic resistance genes

PCT designated stageWO2025217506A1Sugar derivativesHydrolasesNitroimidazoleTrimethoprim
Described herein are compositions, methods, and kits for detecting antibiotic resistance genes in a sample, such as a wound swab. One embodiment described herein is primer pairs and probes for individual or multiplex polymerase chain reaction (PCR) based assays for the detection of one or more antibiotic resistance gene targets comprising resistance to molecularly characterized extended-spectrum β-lactamases (MESBLs); extended-spectrum β-lactamases (ESBLs); carbapenemase; AmpC β-lactamase; β-lactamase; lincosamide, macrolide, streptogramin; trimethoprim; macrolides; methicillin; colistin; sulfonamide; tetracycline; vancomycin; nitroimidazole; quinolone; or aminoglycoside.
Owner:LIFE TECHNOLOGIES CORP

Antimicrobial combinations in treatment of pseudomonas aeruginosa biofilm associated infections

The present invention relates to a synergistic combination of colistin and N-acetylcysteine (NAC) for use in the treatment and eradication of mature biofilm related infections caused by Pseudomonas aeruginosa. In particular, a synergistic combination of colistin and NAC is useful for treating and eradicating Pseudomonas aeruginosa infection in patients suffering from chronic pulmonary disease and recurrent Pseudomonas aeruginosa infection.
Owner:ZAMBON SPA

Application of indometacin combined with polymyxin in resisting salmonella infection

The invention belongs to the technical field of biological medicines, and discloses application of indometacin combined with polymyxin in resisting salmonella infection. A checkerboard method minimum inhibition concentration test and an in-vitro time-sterilization curve test prove that the indometacin and colistin combined drug has an obvious synergistic effect on salmonella resistance, and the indometacin can enhance the antibacterial effect of the colistin drugs on salmonella standard strains and colistin-resistant salmonella. The invention provides a new drug combination strategy, and provides a new research thought and research and development direction for solving the increasingly serious drug resistance problem of polymyxin.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

Antibacterial effect of halogenated fluorescein on colistin-resistant gram-negative bacteria

The present invention contemplates a method for treating gram-negative bacteria other than the genus Burkholderia, Proteus and Serratia, said gram-negative bacteria also exhibiting drug resistance (MIC > = 50 mg / mL) against the bacterial compound colistin, said gram-negative bacteria also exhibiting drug resistance (MIC > = 50 mg / mL) against the bacterial compound colistin, such as colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin, colistin and colistin. The method comprises contacting bacteria with an aqueous pharmaceutical composition containing a rose-bengal (RB) compound of the following formula I dissolved or dispersed therein at a concentration of from about 0.01 to about 15 mg / mL, and irradiating those contacted bacteria with light having a wavelength of from about 500 nm to about 600 nm for a period of from about 1 to about 10 minutes to provide a light dose of from about 16 to about 160 J / cm2, treating and killing the irradiated bacteria, wherein X, R1, R2 and M + are defined herein.
Owner:PROVECTUS PHARMATECH INC +1

Application of Obtoclax mesylate and / or Nigericin in preparation of antibiotic sensitizer

PendingCN122005548AAntibacterial agentsOrganic active ingredientsNigericinOBATOCLAX MESYLATE
The invention relates to the technical field of biological medicine. The invention provides an application of Obtoclax mesylate and / or Nigericin in preparation of an antibiotic sensitizer, wherein the antibiotic comprises colistin. The invention also provides an application of Obtoclax mesylate and / or Nigericin in preparation of the antibiotic sensitizer. The invention further provides an application of the medicine composition of the colistin and the Obtoclax mesylate or the Nigericin in preparation of the medicine for resisting the colistin drug resistance gram-negative bacteria, and the medicine composition of the colistin and the Obtoclax mesylate or the Nigericin can be used for preparing the medicine. According to the technical scheme, the colistin and Obtoclax mesylate or Niguricin are combined for use, so that a synergistic effect is achieved, the MIC value of the colistin for resisting colistin-resistant gram-negative bacteria can be remarkably reduced, and the growth of the gram-negative bacteria is inhibited.
Owner:PEOPLES HOSPITAL PEKING UNIV

Pharmaceutical compositions for prevention and / or treatment of infections and antibacterial-induced dysfunctions

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and / or treatment of bacterial infections and antibacterial-induced dysfunctions. The compositions of the present invention demonstrate high species-specificity in inhibiting the growth of a small number of bacterial species, and most importantly are effective also against multi drug resistant (MDR) clinical isolate species. Interestingly, one of those combinations pairs a non-antibiotic drug, vanillin, with an antibiotic drug, spectinomycin, to demonstrate a surprisingly strong inhibitory effect on the growth of clinically relevant Gram-negative pathogenic and multi-drug resistant E. coli isolates. A second set of compounds combines the polymyxin colistin with loperamide, a rifamycin, or a macrolide. Importantly, this invention relates to combinations that enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development efforts in order to prevent major side effects of antibacterial strategies. This invention also relates to pharmaceutical combinations useful to prevent an adverse effect on the gut microbiome, induced by the use of antibacterial compounds.
Owner:EURO LAB FUER MOLEKULARBIOLOGIE EMBL

Application of loratadine in colistin antibiotic synergist

The invention belongs to the technical field of medical application, particularly discloses novel application of loratadine in a colistin synergist, and discloses a loratadine-colistin composition and a compound preparation, and the mass ratio of loratadine to colistin is (8-512): 1. The combination of the loratadine and the colistin can obviously enhance the antibacterial activity of the colistin on enterobacteriaceae bacteria, and the FICI is 0.0938-0.1563 (both less than 0.5), that is, the combination of the loratadine and the colistin shows an obvious synergistic effect. Meanwhile, the synergist can effectively reduce the use amount of the colistin, and the use amount of the colistin used independently is 4-32 times of the use amount of the loratadine and the colistin used jointly. The bactericidal composition can play a role in synergistically reversing drug resistance, the FICI is 0.0938-0.1563, and the bactericidal composition shows an obvious bactericidal effect after 2-4 hours after drug combination.
Owner:HENAN AGRICULTURAL UNIVERSITY